Observational studyThe Journal of international medical research2026
Effects of dexmedetomidine on respiratory and hemodynamic changes in patients receiving high-flow nasal cannula: A retrospective observational study.
Observational study in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveThe objective of this study was to evaluate the effects of dexmedetomidine on respiratory and hemodynamic parameters in patients receiving high-flow nasal cannula therapy.MethodsThis retrospective observational study included 206 adult patients who received dexmedetomidine during high-flow nasal cannula therapy between November 2019 and September 2023. Patients in whom dexmedetomidine was initiated during mechanical ventilation and those with incomplete data were excluded. Dexmedetomidine was administered intravenously at a median dose of 0.2 (0.2-0.3) mcg/kg/h for 3.0 (2.0-5.0) days. Primary outcomes were changes in respiratory rate and the partial pressures of carbon dioxide and oxygen. Secondary outcomes included hemodynamic changes, adverse events, and discontinuation of dexmedetomidine.ResultsRespiratory rate and the partial pressure of carbon dioxide remained stable over 24 h, whereas the partial pressure of oxygen significantly increased at 3 h (p = 0.007). Dexmedetomidine led to significant reductions in systolic blood pressure and heart rate (p < 0.001). Hypotension occurred in 31.6% of patients, and vasopressors were required in 28.2%. Dexmedetomidine was discontinued in 26.7% of patients because of adverse events.ConclusionsDexmedetomidine administration was associated with improved oxygenation without compromising respiratory drive in patients receiving high-flow nasal cannula, although careful monitoring is warranted because of potential hemodynamic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.